BioSpace News Archive

Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), today announced that Feng Tian, Ph.D., Chairman of the Board, President and CEO of Ambrx, will participate in the virtual H.C. Wainwright Preclinical Cancer Drug Discover: Emerging Targets and Modalities Conference on Wednesday, June 29, 2022.

Beyond Air, Inc. announced financial results for its fiscal fourth quarter and year ended March 31, 2022.

StageZero Life Sciences, Ltd is pleased to report that shareholders voted in favour of all of the tabled resolutions listed in the Company’s management information circular dated May 12, 2022, at its annual and special meeting of shareholders held on June 28, 2022.

Labcorp (NYSE: LH), today announced that it is enhancing its central laboratory presence and drug development capabilities in Japan through an expansion of CB Trial Laboratory, the central laboratory co-managed by Labcorp Drug Development and BML, a leading Japanese provider of clinical laboratory testing services.

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation at the hybrid in-person and virtual European Academy of Allergy and Clinical Immunology (EAACI) Annual Scientific meeting, July 1 – 3, 2022, in Prague, Czech Republic.

CivaTech Oncology Inc., a leading developer of radioactive cancer therapeutics made a presentation regarding the CivaSheet® at the annual Biotechnology Innovation Organization (BIO) Conference June 14, 2022 in San Diego California.

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), announces that phase 1b study results of mazdutide (IBI362), a glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist, in Chinese patients with type 2 diabetes have been published in Nature Communications.

DTx Pharma, Inc. (DTx), a privately-held biotechnology company developing novel RNA-based therapeutics to treat the genetic drivers of disease, today announced the appointment of Peter Condon as Chief Business Officer.

Vedanta Biosciences, a clinical-stage biopharmaceutical company pioneering the development of oral therapies based on defined bacterial consortia, today announced the opening of a new facility designed to manufacture clinical and commercial supply for its therapeutic portfolio, including for the planned Phase 3 study and potential commercial launch of its lead candidate, VE303, in Clostridioides difficile infection.

Innovation Pharmaceuticals today announced new antiviral research on Brilacidin in vitro antiviral activity in bunyaviruses and alphaviruses has been accepted for a Poster Presentation at the 2022 Military Health System Research Symposium.